Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Gubra A/S is a biotechnology company based in Denmark, focusing on pre-clinical contract research and drug discovery. It specializes in the development of peptide-based therapeutics and provides services in areas such as obesity, diabetes, and NASH (non-alcoholic steatohepatitis). The company was founded in 2008 and operates from its headquarters in Hørsholm, Denmark. Gubra differentiates itself through its integrated approach combining histology, imaging, and bioinformatics to deliver comprehensive research services. Its strategic positioning leverages cutting-edge technology to support pharmaceutical companies in early-stage drug development.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
Gubra A/SJohnson & Johnson
Last price
kr 296.80$273.20
Currency
DKK
USD
kr 5B$658B
-41.49
-kr 11.16$6.58
0.320.21
0$5.28
01.96%
Sector
HealthHealth
Employees
330138,200
Ticker
DKr GUBRA$JNJ
Primary listing
CSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in DKrGUBRA or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.